Multiple-Dose Study of VGX-1027 in Healthy Subjects
- First Posted Date
- 2008-09-26
- Last Posted Date
- 2009-04-07
- Lead Sponsor
- VGX Pharmaceuticals, LLC
- Target Recruit Count
- 40
- Registration Number
- NCT00760396
- Locations
- ๐บ๐ธ
SNBL Clinical Pharmacology Center, Inc., Baltimore, Maryland, United States
Phase I Safety and Pharmacokinetic Study of VGX-1027 in Healthy Subjects
- First Posted Date
- 2008-02-29
- Last Posted Date
- 2009-01-09
- Lead Sponsor
- VGX Pharmaceuticals, LLC
- Target Recruit Count
- 48
- Registration Number
- NCT00627120
- Locations
- ๐บ๐ธ
SNBL Clinical Pharmacology Center, Baltimore, Maryland, United States
Antiviral Activity and Safety of Mifepristone at 2 Doses in HIV-1 Infected Subjects
Phase 2
Completed
- Conditions
- HIV Infections
- Interventions
- Drug: VGX-410 (Mifepristone)Drug: Placebo for VGX-410 (Mifepristone)
- First Posted Date
- 2006-07-17
- Last Posted Date
- 2010-03-09
- Lead Sponsor
- VGX Pharmaceuticals, LLC
- Target Recruit Count
- 19
- Registration Number
- NCT00352911
- Locations
- ๐บ๐ธ
Georgetown University, Washington, District of Columbia, United States
๐บ๐ธUniversity of Pennsylvania, Philadelphia, Pennsylvania, United States
๐บ๐ธVeterans Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
Antiviral Activity and Safety of 3 Different Doses of Mifepristone in Hepatitis C Infected Patients
Phase 2
Completed
- Conditions
- Hepatitis C Virus Infection
- Interventions
- Drug: VGX-410 (Mifepristone)Drug: Placebo
- First Posted Date
- 2005-11-17
- Last Posted Date
- 2009-11-03
- Lead Sponsor
- VGX Pharmaceuticals, LLC
- Target Recruit Count
- 44
- Registration Number
- NCT00255177
- Locations
- ๐บ๐ธ
Orlando Clinical Research Center, Orlando, Florida, United States
๐บ๐ธSaint Louis University, Saint Louis, Missouri, United States
๐บ๐ธUniversity of Pennsylvania, Philadelphia, Pennsylvania, United States
ยฉ Copyright 2025. All Rights Reserved by MedPath